A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)

NCT02028065 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

382

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypersensitivity
Anaphylaxis

Interventions

DRUG: Sugammadex
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC